

### Reclassification of post marketing changes (Variations) For Imported Drugs

### إعادة تصنيف التغيرات ما بعد التسويق للأدوية المستوردة

28 March 2014

Presented by: Dr. Rita Karam

Director of Quality Assurance of Pharmaceutical Products





- Variation's Types according to decree 571/2008
- Comparison between current and suggested classification of
  - Variations Type I for Imported Drugs
- **\*** Comparison between current and suggested classification of

Variations Type II for Imported Drugs

Conclusion





- Variation's Types according to decree 571/2008
- Comparison between current and suggested classification of
  Variations True I for low and Decay
  - Variations Type I for Imported Drugs
- Comparison between current and suggested classification of

Variations Type II for Imported Drugs

Conclusion



Efforts have been made by the MOPH in order to update texts related to the Registration of drugs

Many laws and decrees have been promulgated in order to organize it

In Lebanon, back to 2003 and concerning Drug Registration:

شروط تسجيل واستيراد وتسويق وتصنيف الأدوية Law 530/2003

Applicative Decree 571/2008 طبيق أحكام المادتين الثالثة والخامسة من القانون رقم530 والمواد ٥٢ و ٥٣ و ٤٥ و ٦٠ من لانون مز اولة مهنة الصيدلة ٣٦٧



Decree 571/2008:

 Identification and Classification of Post Marketing Changes related to already registered Imported and Locally Manufactured Drugs into two types:

### Variations Type I and II

Method of notification and approval required by the MOPH.





#### To fill the gaps detected after several years of implementation & To align with the international classifications:

- Review the current classification of Variations
- Prepare a new classification technically and structurally inspired by several international guidelines especially WHO Guidance on Variations
- <sup>\*</sup> Update the documents required for each of these Variations in the new classification



- New Variations are added
- Some old Variations are either deleted or modified
- Some Variations make a new application necessary



Based on WHO recommendations and guidelines

Reclassification of Variations for Imported Drugs





- Variation's Types according to decree 571/2008
- Comparison between current and suggested classification of
  - Variations Type I for Imported Drugs
- **\* Comparison between current and suggested classification of**

Variations Type II for Imported Drugs

Conclusion

# **Type I Variations**





Reclassification of Variations for Imported Drugs

# **Type II Variations**









- Variation's Types according to decree 571
- Comparison between current and suggested classification of
  - **Variations Type I for Imported Drugs**
- **\* Comparison between current and suggested classification of**

Variations Type II for Imported Drugs

Conclusion

### Number of Variations





Reclassification of Variations for Imported Drugs



Frequent requested documents

- •Statement issued by the "RP" certifying that no change occurred in the technical specifications of the registered products.
- OR
- •Statement issued by the "RP" regarding the change
- •2 Original specimens and their related COA are requested otherwise <u>Mock ups</u> and commitment letter to submit final samples before importation of the product after approval granted by MOPH.



#### <u>Variation Títle</u> Current

Change in the name of the product without any other changes in its basic characteristics

#### Suggested

1. Change or addition in the trade name of the product without any other changes in its basic characteristics

Documents related to pricing if the new product comes in addition to the old one



<u>Variation Title</u> Current

Change the name of the "Responsible party" without any other change

تغيير أسم "الجهة المسؤولة" دون أي تعديل آخر

#### Suggested

2. Change in the name, address and/or office address of any of the parties involved in the manufacturing of the Finished Product

### For the parties involved in the manufacturing of the Finished Product

•Statement issued by the "RP" certifying that the change is limited to the name, address and /or office address of the concerned party and there is **no change in the physical address** of the manufacturing site



#### <u>Variation Títle</u> Current

Change one of the Plants which participate in the process of manufacturing to any other reference countries without changing the "Responsible Party" or the "Mother Company" Suggested

4. Change in one of the factories participating in the production of the registered product to a country among the reference countries without changing the responsible party

تغيير احد المصانع المشاركة في التصنيع الى بلد من "بلدان المرجعية" دون تغيير "الجهة المسؤولة" او "الشركة الام" تغيير احد المصانع المشاركة في تصنيع المنتج المسجل الى بلد من "بلدان المرجعية" دون تغيير "الجهة المسؤولة"

Plant profile of the new factory if not previously submitted to MOPHDocuments related to pricing



<u>Variation Title</u> Current

Change in the origin of raw materials / Addition of a new source

Suggested

5. Addition of new (or replacement) Drug Substance Manufacturer

•COA for the DS from the new DS manufacturer and from the manufacturer of the FP.

•COA for the FP from the manufacturer of the FP corresponding to a batch obtained with the drug substance from the new manufacturer.



Variation Title

New Variation

6. Change in the ATC Code (Anatomical Therapeutic Chemical Classification)

تغيير في رمز نظام تصنيف الادوية الكيميائي العلاجي التشرحي

Copy of **Proof of Acceptance** issued by WHO



Variation Title

New Variation

7. Change in the name, address and/ or office address of one of the manufacturers of the Drug Substance

تغيير اسم، عنوان و/او عنوان مكتب لاحد مصنعى المادة الفعالة

•Statement issued by the "RP" certifying that no change in the physical address of the manufacturing site

•Statement issued by the Drug Substance Supplier mentioning the new name and/or address of the manufacturing site



Variation Title

New Variation

8. Change in the Re-Test Period/or Storage Conditions of the Drug Substance

تغيير في مدة اعادة الاختبار و/او شروط حفظ المادة الفعالة

**Stability Study** for the Drug Substance according to ICH Guidelines



Variation Title

#### Current

Change in the pack size of the registered product

#### Suggested

9. Change (or addition) in the pack size (number of units in the pack) of the Registered Product

### Documents related to pricing

### Comparison between current and suggested variations Type I Variation Title



#### Current

Change in the primary packaging material

#### Suggested

**10. Change in the primary packaging of the Finished Product** 



Variation Title

New Variation

**11.Change in the Design** 

Comparison between the current and suggested design



Variation Title

New Variation

**12. Reduction of the Shelf life of the Finished Product** 

Stability Study for the Finished Product as per ICH Guidelines
CPP or FSC showing the new Shelf life
Copy of Finished Product Specifications mentioning the new Shelf life



Variation Title

New Variation

13. Extension of the Shelf life of the Finished Product

Stability Study for the Finished Product as per ICH Guidelines
CPP or FSC showing the new Shelf life
Copy of Finished Product Specifications mentioning the new Shelf life



Variation Title

New Variation

**14.Change in the Storage Conditions of the Finished Product** 

Stability Study for the Finished Product as per ICH Guidelines
CPP or FSC with the new Storage Conditions
Copy of Finished Product Specifications mentioning the new Storage Conditions



Variation Title

New Variation

15. Change in the Manufacturing Process of the Finished Product

#### تغيير في طريقة تصنيع المستحضر النهائي

- The overall **Manufacturing Principle** remains the same and that the new process leads to an **identical product** regarding all aspect of Quality, Safety and Efficacy.
- •Table comparing the current manufacturing process and the new manufacturing process
- Stability study for the FP obtained with the new manufacturing process
- •COA for the FP obtained with the new manufacturing process



Variation Title

New Variation

16. Change in the Specifications and/or Method of Analysis of Finished Product

Comparative table between old and new Specifications
New Method of Analysis in comparison to old one
Copy of Finished Product new Specifications



<u>Variation Title</u>

New Variation

**17. Leaflet Content Update** 

تحديث النشرة الدّاخليّة

Updated Summary of Product Characteristics SmPC
Published literatures of the studies covering the new additions
Comparison table between the current and suggested leaflet

### Comparison between current and suggested variations Type I Variation Title



Current = Cancelled

A secondary change in the Pharmaceutical form, from tablets to capsules or others

### New Application necessary for any changes to the Pharmaceutical Dosage Form

Reclassification of Variations for Imported Drugs





- \* Variation's Types according to decree 571
- Comparison between current and suggested classification of
  - Variations Type I for Imported Drugs
- Comparison between current and suggested classification of

Variations Type II for Imported Drugs

Conclusion

### Number of Variations





#### Comparison between current and REPUBLIC OF LEBANON MINISTRY OF PUBLIC HEALTH suggested variations Type II



GMP certificate of the new factory (if applicable)



<u>Variation Títle</u> Current

Change in one of the manufacturers participating in the manufacturing process to a country different from the "Reference Countries" without changing the "Responsible party" or the "Mother Company".

تغيير احد المصانع المشاركة في التصنيع الى بلد خارج "بلدان المرجعية" دون تغيير "الجهة المسؤولة" و "الشركة الام

#### Suggested

Change in one of the manufacturers participating in the production of the registered product, to a country out the reference countries, without changing the Responsible Party

تغيير احد المصانع المشاركة في تصنيع المستحضر المسجل الى بلد خارج "بلدان المرجعية" دون تغيير "الجهة المسؤولة"

#### GMP certificate of the new factory

Reclassification of Variations for Imported Drugs

### Comparison between current and REPUBLIC OF LEBANON MINISTRY OF PUBLIC HEALTH suggested variations Type II

Variation Title<br/>CurrentSuggestedChange the dosage of the productChange and or addition of a Strengthristleristlechalleristlechalleristlechalleristlechalleristlechalleristleristleristlechalleristlechalleristlechalleristlechalleristle

•Statement issued by the RP certifying that there is no change in the factories involved in the manufacturing of the product

- •For innovators, Data demonstrating the efficacy in case of lower strength and the safety in case of higher strength
- Documents related to pricing





- \* Variation's Types according to decree 571
- Comparison between current and suggested classification of
  - Variations Type I for Imported Drugs
- **\*** Comparison between current and suggested classification of

Variations Type II for Imported Drugs

Conclusion

### **Conclusion: What's Next?**



The new classification was reviewed by the Technical Committee and was amended according to their remarks

The new classification will be sent to the private parties: LPIA, OPL and all Concerned Parties for remarks and comments.

 According to the resolution No. 1638/2013, a legal text related to the new classification including all suggested changes will be prepared by a special committee



# **Thank You!**